TILT Holdings (TLLTF) Liabilities and Shareholders Equity (2021 - 2025)
TILT Holdings (TLLTF) reported Liabilities and Shareholders Equity of $138.3 million for Q2 2025, down 27.19% on a YoY basis from $189.9 million in Q2 2024, and down 7.65% quarter-over-quarter from $149.7 million in Q1 2025.
TILT Holdings (TLLTF) Liabilities and Shareholders Equity (2021 - 2025) Analysis & Trends
TILT Holdings has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $138.3 million in Q2 2025.
- For the quarter ending Q2 2025, Liabilities and Shareholders Equity fell 27.19% year-over-year to $138.3 million; the trailing twelve-month figure through Jun 2025 stood at $621.9 million (down 31.21% YoY), and the FY2024 full-year result was $151.3 million, down 34.55% from the prior year.
- Liabilities and Shareholders Equity for Q2 2025 stood at $138.3 million, down from $149.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $401.2 million in Q2 2022, with the low at $138.3 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $251.1 million across 5 years, with a median of $241.5 million in 2023.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity sank 35.64% — and 2024, when it dropped 19.97%.
- TILT Holdings' Liabilities and Shareholders Equity stood at $381.3 million in 2021, then retreated by 22.91% to $294.0 million in 2022, then declined by 21.36% to $231.2 million in 2023, then sank by 34.55% to $151.3 million in 2024, then dropped by 8.61% to $138.3 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $138.3 million (Q2 2025), $149.7 million (Q1 2025), and $151.3 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | TILT Holdings | - | - | 1.82 Mn | 138.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 138.29 Mn |
| Mar 31, 2025 | 149.74 Mn |
| Dec 31, 2024 | 151.32 Mn |
| Sep 30, 2024 | 182.59 Mn |
| Jun 30, 2024 | 189.92 Mn |
| Mar 31, 2024 | 231.83 Mn |
| Dec 31, 2023 | 231.19 Mn |
| Sep 30, 2023 | 251.23 Mn |
| Jun 30, 2023 | 258.22 Mn |
| Mar 31, 2023 | 289.68 Mn |
| Dec 31, 2022 | 293.98 Mn |
| Sep 30, 2022 | 364.38 Mn |
| Jun 30, 2022 | 401.19 Mn |
| Dec 31, 2021 | 381.35 Mn |